EC Number   |
Application |
Reference |
|---|
   2.5.1.26 | medicine |
enzyme AGPS may be a potential glioma and hepatic carcinoma therapeutic target |
739210 |
| 2.5.1.26 | medicine |
enzyme levels are strongly reduced in fibroblasts derived from Zellweger syndrome and rhizomelic chondrodysplasia punctata patients |
489892, 489895 |
| 2.5.1.26 | medicine |
in fibroblast cell lines derived from Zellweger syndrome and rhizomelic chondrodysplasia punctata patients enzyme is mainly present as precursor form |
489893 |
| 2.5.1.26 | pharmacology |
alkylglycerone phosphate synthase is an oncogene and can be considered as an antitumor drug target. The study designs novel nitrogenous heterocyclic compound improving targetability by computer-aided drug design technology targeting alkylglycerone phosphate synthase. A total of 12 nitrogenous heterocyclic compounds are designed and predicted the absorption, distribution, metabolism and excretion parameters/toxicity. Their activity in terms of proliferation inhibition, cell cycle arrest and apoptosis induction as then measured using an MTS assay and a high-content screening system in U251 cells. The results show that anti-glioma activity is present in several compounds, which is in accordance with the computer prediction. These compounds may be suitable for the development of a glioma therapeutic drug |
759877 |
| 2.5.1.26 | pharmacology |
the enzyme reduces ether lipid levels in tumor cells and thus decreases cancer pathogenicity. It is considered to be a target of antitumor drugs, with specific inhibitors expected to have marked advantages over traditional chemotherapy methods |
758882 |
